JWH-184

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 3-[(4-Methyl-1-naphthalenyl)methyl]-1-pentyl-1H-indole

| image = JWH-184.png

| image_class = skin-invert-image

| width = 150

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK = Class B

| legal_US = Schedule I

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 619294-37-0

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = QKU9P2ZGM5

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank_Ref =

| DrugBank =

| ChemSpiderID = 35303439

| C=25 | H=27 | N=1

| smiles = CCCCCn1cc(c2c1cccc2)Cc3ccc(c4c3cccc4)C

| StdInChI = 1S/C25H27N/c1-3-4-9-16-26-18-21(24-12-7-8-13-25(24)26)17-20-15-14-19(2)22-10-5-6-11-23(20)22/h5-8,10-15,18H,3-4,9,16-17H2,1-2H3

| StdInChIKey = FSOLXFPDIJJWBM-UHFFFAOYSA-N

}}

JWH-184 is a synthetic cannabinoid receptor ligand from the naphthylmethylindole family. It is the carbonyl-reduced derivative of related compound JWH-122. The binding affinity of JWH-184 for the CB₁ receptor is reported as K_i = 23 ± 6 nM.{{cite journal | vauthors = Huffman JW, Mabon R, Wu MJ, Lu J, Hart R, Hurst DP, Reggio PH, Wiley JL, Martin BR | display-authors = 6 | title = 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor | journal = Bioorganic & Medicinal Chemistry | volume = 11 | issue = 4 | pages = 539–49 | date = February 2003 | pmid = 12538019 | doi = 10.1016/s0968-0896(02)00451-0 | s2cid = 29107765 }}

In the United States, all CB₁ receptor agonists of the 3-(1-naphthylmethane)indole class such as JWH-184 are Schedule I Controlled Substances.{{UnitedStatesCode2|21|812|Schedules of controlled substances}}